Garrett Lam
Garrett Lam will join Sera Prognostics as chief medical officer starting Sept. 4. He will direct all clinical development activities for the firm and direct a group of clinical operations professionals in support of the firm's collaborations. Lam is currently a professor and chairman of obstetrics and gynecology at the University of Tennessee College of Medicine-Chattanooga. Lam replaces Durlin Hickok, who has been Sera's CMO since 2011. Hickok will continue as an advisor to Sera.
Kenneth Bloom
Kenneth Bloom has become chief medical officer of advanced pathology and genomic services at Invicro and Ambry Genetics, both part of Konica Minolta. Previously, he was president and head of oncology and immunotherapy at Human Longevity, and before that, chief medical officer of in vitro diagnostics, life sciences at General Electric. He also served as president and CEO of the medical group of Clarient Pathology Services, which was acquired by GE. Prior to that, he held various academic positions, including director of laboratory operations and chief information officer at the Rush Cancer Institute, clinical professor of pathology at the University of Southern California Keck School of Medicine, and associate professor of pathology at Rush Medical College. Bloom holds an MD from Rush Medical College and a BA from Grinnell College
Joseph Caruso
LexaGene has appointed Joseph Caruso to its board of directors. Caruso currently serves as a member of the board of directors and operating committee at Endocellutions. Caruso was previously CEO and chairman of Palomar Medical Technology until the firm's sale in 2013.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.